Coherus Biosciences | CHRS - Przychody Ze Sprzedaży





Obroty Zmiana Data
AbbVie USD 15B 1.62B 2026-03
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
Akebia Therapeutics USD 57.62M 1.14M 2025-12
ALKERMES USD 392.91M 8.41M 2026-03
Alnylam Pharmaceuticals USD 1.17B 70M 2026-03
Amarin USD 49.22M 451K 2025-12
Amgen USD 8.62B 1.28B 2026-03
Baxter International USD 2.7B 270M 2026-03
Biogen USD 2.25B 30M 2026-03
BioMarin Pharmaceutical USD 766M 109M 2026-03
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Coherus Biosciences USD 12.75M 1.18M 2025-12
Eli Lilly USD 19.8B 500M 2026-03
Fujifilm JPY 927.25B 69.9B 2026-03
Gilead Sciences USD 7B 930M 2026-03
Ironwood Pharmaceuticals USD 106.51M 58.8M 2026-03
Merck USD 16.29B 110M 2026-03
Myriad Genetics USD 200.4M 9.4M 2026-03
Pacira USD 177M 19.87M 2026-03
Perrigo USD 969M 141M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
PTC Therapeutics USD 273M 108.3M 2026-03
Regeneron Pharmaceuticals USD 3.6B 280M 2026-03
Sarepta Therapeutics USD 730.8M 287.9M 2026-03
Teva Pharmaceutical Industries USD 11.77B 2.86B 2026-03
Vertex Pharmaceuticals USD 2.99B 200M 2026-03
Xencor USD 4.51M 23.73M 2026-03
Zoetis USD 2.3B 100M 2026-03